Vida Ventures

Vida Ventures related stories

All articles and analysis

• 
  Vida Ventures hires CFO/COO

  Iris Dorbian- 8 October 2019

  Vida Ventures has named Jean-Philippe Kouakou-Zebouah as chief financial and chief operating officer. Previously, he worked at Versant Ventures where he was senior vice president of finance.

• 
  U.S. venture fundraising about to top $40 bln, again

  Alastair Goldfisher- 18 September 2019
• 
  Emerging managers continue to pile up capital

  Sandeep Khare- 1 August 2019
• 
  Emerging managers pull in $1.1 bln, led by Vida Ventures

  Joseph Weitemeyer- 18 July 2019
• 
  Vida Ventures raised $537 mln toward a second fund

  Marina Temkin- 16 July 2019

  Vida Ventures, a Boston, Massachusetts-based life sciences-focused venture firm raised $537 million towards its second fund, according to a regulatory document https://www.sec.gov/Archives/edgar/data/1776851/000177685119000001/xslFormDX01/primary_doc.xml

• 
  Gene therapy platform AskBio snags $235 mln

  Iris Dorbian- 11 April 2019

  North Carolina-based AskBio, a gene therapy platform, has secured $235 million in funding. The investors included TPG Capital and Vida Ventures.

• 
  October IPO Profiles: Allogene, biotech continue to lead the way

  VCJ Staff- 16 November 2018
• 
  October Dashboard: GitHub deal fuels big month of acquisitions, fundraising tops $11 bln

  VCJ Staff- 6 November 2018
• 
  September IPO Profiles: Eventbrite, biotech highlight busy month

  VCJ Staff- 20 October 2018
• 
  VC-backed Allogene Therapeutics goes public

  Iris Dorbian- 11 October 2018

  South San Francisco-based Allogene Therapeutics, a biotech company focused on cancer treatment, has raised $324 million after pricing its 18 million shares at $18 per share. The stock began trading October 11, 2018 on the NASDAQ under the ticker symbol "ALLO." Goldman Sachs, J.P. Morgan Securities LLC, Cowen and Company and Jefferies LLC are the lead underwriters. Allogene's pre-IPO backers included Vida Ventures.